Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective.
about
Posttranslational Modifications and the Immunogenicity of BiotherapeuticsAssessing the Immunogenicity of BiopharmaceuticalsImmunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practiceStandardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortiumAnti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort StudyA Rationally Designed TNF-α Epitope-Scaffold Immunogen Induces Sustained Antibody Response and Alleviates Collagen-Induced Arthritis in MiceInfluence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort.Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional studyA randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemiaAdalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuationA novel anti-TNF scFv constructed with human antibody frameworks and antagonistic peptides.Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.Pharmacokinetics of monoclonal antibodies used for inflammatory bowel diseases in pregnant women.Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockersClinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis.Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis.Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels.Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort.Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events.Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab.Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.Treatment challenges in axial spondylarthritis and future directions.The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.Adverse effects of golimumab in the treatment of rheumatologic diseases.Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?Therapeutic drug monitoring in rheumatic diseases: utile or futile?Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposure.Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.Understanding and applying tyrosine biochemical diversity.Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review.
P2860
Q26748614-56DC2C13-366A-4EE3-81F0-629758F576EFQ26751485-930AF3BE-A840-46B0-B91C-3F0E86847B35Q26798357-D9C181D1-406C-44F0-824B-0241654BA1ABQ27009385-A5286CAA-A65D-41F1-BB02-9B0C8B3F14D8Q28553954-09FFB5AF-6706-461A-A899-CEE5684287DCQ28554288-C27622F9-EADC-42C9-98E7-EC6901019088Q30240229-807ADADC-678A-44A2-A368-3DB0C281D21CQ30826279-52282BA1-B4B2-4473-A389-FF70BBC016A0Q31021097-1E3961B3-CD4E-4651-BECB-BF20B07C444AQ33610284-BFBC93DD-03B9-4FFF-A5EB-1CB8560AFD43Q33731695-AD4498A0-2A4F-4DC3-B083-F7CB600F34DBQ33881234-65C35D2A-E2CF-4A3E-9888-7AD11A117068Q33910990-95795BCD-A85B-4D21-9A17-38637667E639Q34669637-5C4BF540-EDF7-4BE7-95ED-AFE834133A49Q35658998-F6519178-A1C9-4B6D-97C3-80AE03BC8058Q36214720-E0317160-C9B9-45D7-9391-E69682CCFC03Q36239177-2C7CDD9C-7E7A-440F-A143-76D5E8244B30Q36347059-4544DC15-BD14-4C84-81A3-1A1CC8A5FD9FQ36776326-BE00CC50-5892-4B1E-939D-E8D5D6DB0825Q36832755-24443C8B-87D3-4026-8F7B-DA292101FDD7Q37201814-4E4A5165-4F8B-4532-9A73-DFCB597E65D2Q37217446-AF7C9919-22BE-4FA2-B6B5-94117069F712Q37353452-7A6DCAF2-50D3-4A8A-8BC3-2C925760CF13Q37383419-6A524155-F546-4882-9E61-B94E25D4F52BQ37517101-2862B7BD-0C1E-4C4B-9676-E1E5D1570B53Q37604498-67F95B6F-0E08-4FAD-835D-A2D06655E4DCQ37653421-F9E3BFF9-850E-4CCB-B01D-00C461EDB0A8Q37703466-9F2AD04F-462D-4E58-8DAD-3C888BCDAA28Q38095548-D98F0FCF-C316-49E8-B327-9D5354D6F852Q38124281-F58B63C5-1F4E-4541-9D43-4F9C4B58778BQ38129037-808AA718-BD28-45F6-99C9-ADFCFE35C01EQ38132273-7446989A-B6F4-4293-BE12-6B5AEE1FB7B5Q38150903-9721153B-6792-4981-B5D9-BB04FC0DA6F4Q38160305-4BA20C17-719B-4689-8A44-FCD6778367AAQ38160896-276AE2E5-2657-4737-9B75-ED51A528DC55Q38164315-E6664502-93CF-4DFB-A3BF-94301D7F4497Q38195522-66306FE3-014C-4713-A756-897633DFE363Q38200925-8F1F419E-80F3-4C99-86A8-A0B55FBD3921Q38200926-E5925C9C-5089-492F-A2AF-92736D5CEEFBQ38201788-D70804A3-1C70-4224-AD81-55E9DDBB7174
P2860
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Antidrug antibodies (ADAb) to ...... issue, a clinical perspective.
@en
type
label
Antidrug antibodies (ADAb) to ...... issue, a clinical perspective.
@en
prefLabel
Antidrug antibodies (ADAb) to ...... issue, a clinical perspective.
@en
P2093
P50
P921
P1476
Antidrug antibodies (ADAb) to ...... issue, a clinical perspective.
@en
P2093
Christian Marcelli
Kim Murphy
Xavier Mariette
P304
P356
10.1136/ANNRHEUMDIS-2012-202545
P407
P577
2012-11-24T00:00:00Z